Get the Stockscreener App
1.204
2.90%
-0.036
Cognition Therapeutics Inc stock is traded at $1.204, with a volume of 292.23K.
It is down -2.90% in the last 24 hours and up +43.73% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
See More
Previous Close:
$1.24
Open:
$1.26
24h Volume:
292.23K
Relative Volume:
0.27
Market Cap:
$107.86M
Revenue:
-
Net Income/Loss:
$-23.49M
P/E Ratio:
-3.5031
EPS:
-0.3437
Net Cash Flow:
$-24.59M
1W Performance:
+2.03%
1M Performance:
+43.73%
6M Performance:
-27.47%
1Y Performance:
+188.38%
1-Day Range:
$1.1701
$1.27
1-Week Range:
$1.1701
$1.345
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.2071 | 110.80M | 0 | -23.49M | -24.59M | -0.3437 |
VRTX
Vertex Pharmaceuticals Inc
|
428.58 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.58 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.32 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.35 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.54 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics (NASDAQ: CGTX) CFO has 8,567 shares withheld for taxes - Stock Titan
Cognition Therapeutics (CGTX) to Release Earnings on Wednesday - MarketBeat
Cognition Therapeutics | DEF 14A: Definitive information statements - Moomoo
Cognition Therapeutics | DEFA14A: Others - Moomoo
Cognition Therapeutics | ARS: Annual Report to Security Holders - Moomoo
[ARS] COGNITION THERAPEUTICS INC SEC Filing - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) outlines 2026 virtual meeting, director elections and EY ratification - Stock Titan
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cognition Therapeutics, Inc. (CGTX) - Minichart
Top Brass Makes Bold Move With Fresh Insider Buying Spree at Cognition Therapeutics - TipRanks
Insider Buying: John Doyle Acquires 10,000 Shares of Cognition T - GuruFocus
John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock - MarketBeat
Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock - MarketBeat
Cognition therapeutics CMO buys $11,100 in common stock - Investing.com
Cognition therapeutics CFO John Doyle buys $11,299 in stock - Investing.com
Cognition therapeutics CEO Lisa Ricciardi buys $10,092 in shares - Investing.com
Cognition therapeutics CEO Lisa Ricciardi buys $10,092 in shares By Investing.com - Investing.com India
Cognition therapeutics CFO John Doyle buys $11,299 in stock By Investing.com - Investing.com South Africa
Cognition therapeutics CMO buys $11,100 in common stock By Investing.com - Investing.com Canada
Cognition Therapeutics (CGTX) CFO adds 10,000 shares in open-market buy - Stock Titan
Cognition Therapeutics (CGTX) CEO buys 9,175 open-market shares - Stock Titan
Insider buy: Cognition Therapeutics (CGTX) CMO adds 10,000 shares - Stock Titan
Cognition Therapeutics (CGTX.US) achieved positive results in the CT1812 trial for Alzheimer's disease medication. - 富途牛牛
CGTX: Phase III trials for zervimesine in DLB psychosis and Alzheimer's are advancing with strong safety and efficacy data - TradingView
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans - Yahoo Finance
Update Report: Can Cognition Therapeutics Inc disrupt its industryQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Insider Trends: Whats the fair value of Cognition Therapeutics Inc stockSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Insider Sell: Can Cognition Therapeutics Inc disrupt its industryPortfolio Gains Summary & Daily Stock Momentum Reports - baoquankhu1.vn
Big Picture: Whats the fair value of Cognition Therapeutics Inc stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Lewy Body Dementia Market: Accelerating Growth and Pipeline Impact by 2034– DelveInsight | Cognition Therapeutics, KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Barchart.com
Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference - Bitget
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
CEO to give Alzheimer's, Lewy body drug update on April 13 - Stock Titan
Fed Meeting: What is the PEG ratio of Cognition Therapeutics Inc2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Will Cognition (CGTX) Stock Hit Record Highs | Price at $0.89, Up 1.96%Institutional Buying - Cổng thông tin điện tử Tỉnh Sơn La
CGTX Technical Analysis & Stock Price Forecast - Intellectia AI
CGTX Should I Buy - Intellectia AI
CGTX Stock Analysis: Cognition Therapeutics Inc. posts 17.37 pct gain near 1 dollar resistance - Cổng thông tin điện tử Tỉnh Sơn La
Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia
Cognition Therapeutics plans late-stage trial for dementia drug - Investing.com
Cognition Therapeutics CEO Issues Letter to Shareholders - 富途牛牛
Q1 Earnings Forecast for CGTX Issued By HC Wainwright - MarketBeat
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat
Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - Minichart
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):